Literature DB >> 30307617

Risk of cardiovascular disease among Nordic childhood cancer survivors with diabetes mellitus: A report from adult life after childhood cancer in Scandinavia.

Jeanette F Winther1,2, Smita Bhatia3, Luise Cederkvist1, Thorgerdur Gudmundsdottir1, Laura Madanat-Harjuoja4, Laufey Tryggvadottir5,6, Finn Wesenberg7,8,9, Henrik Hasle10, Anna Sällfors Holmqvist11,12.   

Abstract

BACKGROUND: Childhood cancer survivors have an increased risk of cardiovascular disease (CVD) and diabetes mellitus. Because diabetes is a potentially modifiable risk factor for CVD in the general population, it is important to understand how diabetes affects the risk of CVD among childhood cancer survivors.
METHODS: This study examined the risk of CVD among survivors with diabetes and 142,742 population comparison subjects. From the national cancer registries of the 5 Nordic countries, 29,324 one-year survivors of cancer diagnosed before the age of 20 years between 1968 and 2008 were identified. Study subjects were linked to the national hospital registers. The cumulative incidence of CVD was determined with competing risk methods. A Cox proportional hazards model was used to estimate the effects of diabetes and cancer on the hazard of CVD. The interaction between diabetes and cancer was analyzed.
RESULTS: Diabetes was diagnosed in 324 of the 29,324 one-year survivors, and CVD was diagnosed in 2108. The hazard of diabetes was 1.7 times higher among survivors than comparison subjects (hazard ratio [HR], 1.7; 95% confidence interval [CI], 1.5-1.9), whereas the HR of CVD was 3.6 (95% CI, 3.3-3.8) 1 to 15 years after the cancer diagnosis and 1.9 (95% CI, 1.8-2.0) after more than 15 years. Individuals with diabetes had a 2.4 times higher hazard of CVD (95% CI, 2.1-2.8) among both survivors and comparison subjects in comparison with individuals without diabetes.
CONCLUSIONS: Childhood cancer survivors with diabetes have a markedly increased risk of CVD in comparison with survivors without diabetes. However, diabetes does not increase the risk of CVD more in survivors than the general population.
© 2018 American Cancer Society.

Entities:  

Keywords:  cardiovascular disease; cerebrovascular disease; childhood cancer; diabetes mellitus; survivorship

Mesh:

Year:  2018        PMID: 30307617     DOI: 10.1002/cncr.31696

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  5 in total

Review 1.  Interventional Strategies in Cancer-induced Cardiovascular Disease.

Authors:  Bala Pushparaji; Teodora Donisan; Dinu V Balanescu; Nicolas Palaskas; Peter Kim; Juan Lopez-Mattei; Mehmet Cilingiroglu; Saamir A Hassan; Konstantinos Dean Boudoulas; Konstantinos Marmagkiolis; Ludhmila Abrahao Hajjar; Cezar A Iliescu
Journal:  Curr Oncol Rep       Date:  2021-09-27       Impact factor: 5.075

2.  Hospitalization and mortality outcomes in the first 5 years after a childhood cancer diagnosis: a population-based study.

Authors:  Angela Steineck; Eric J Chow; David R Doody; Beth A Mueller
Journal:  Cancer Causes Control       Date:  2021-04-09       Impact factor: 2.532

Review 3.  Management of Acute Coronary Syndrome in Cancer Patients: It's High Time We Dealt with It.

Authors:  Fabiana Lucà; Iris Parrini; Maurizio Giuseppe Abrignani; Carmelo Massimiliano Rao; Laura Piccioni; Stefania Angela Di Fusco; Roberto Ceravolo; Irma Bisceglia; Carmine Riccio; Sandro Gelsomino; Furio Colivicchi; Michele Massimo Gulizia
Journal:  J Clin Med       Date:  2022-03-24       Impact factor: 4.241

4.  Metabolic syndrome in childhood cancer survivors.

Authors:  Amena Firoz; Muhammad Haris
Journal:  EXCLI J       Date:  2022-02-10       Impact factor: 4.068

5.  High molecular weight adiponectin levels are inversely associated with adiposity in pediatric brain tumor survivors.

Authors:  Rebecca Ronsley; Shahrad Rod Rassekh; Adam Fleming; Brianna Empringham; William Jennings; Carol Portwine; Sarah Burrow; Shayna Zelcer; Donna L Johnston; Lehana Thabane; M Constantine Samaan
Journal:  Sci Rep       Date:  2020-10-29       Impact factor: 4.379

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.